Studying Bone Marrow Markers to Predict Chemotherapy Response and Outcomes in Adults with Acute Myeloid Leukemia

What this Trial Is About

This research focuses on adult patients newly diagnosed with acute myeloid leukemia AML to study how factors in the bone marrow environment, such as IL-6, leptin, and fumarate, affect resistance to chemotherapy. The study aims to identify these factors as potential biomarkers for predicting treatment response and overall prognosis. It also plans to use patient-derived mouse models to better understand their roles in chemotherapy resistance. The study will enroll 405 AML patients following Chinese guidelines for diagnosis and treatment, along with 81 healthy controls matched by age and sex. Researchers will analyze bone marrow fluid samples to measure these factors and evaluate their connection to treatment outcomes after one cycle of chemotherapy. The mouse models derived from patient cells will help confirm the impact of these factors on chemoresistance. Participants will be monitored for treatment responses such as overall response rate within the first month and long-term outcomes including overall survival over three years. Data collection includes bone marrow sample analysis and clinical assessments. The study will track safety and prognosis to provide insight into potential new targets for AML therapies. Participation duration spans from diagnosis through follow-up periods up to three years.

Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity